Dr Hope Rugo explores how new data suggest immunotherapy could reshape the standard of care for early-stage HR+ and ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an announcement. Shanghai Henlius Biotech, Inc. announced that its ...

Tumor treating fields are emerging as a promising option for treating a range of cancer types. Here’s a look at the evidence ...

Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood ...

In recent years, traditional surgery, chemotherapy, and radiotherapy alone may fail to acquire satisfactory effects for ...

The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to enhance antitumor responses while minimizing liver toxicity by focusing activation within the tumor ...

AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...

The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for the treatment of adult ...

The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult ...